BioSight
Companies
PTC THERAPEUTICS, INC. logo

PTCT

NASDAQWARREN, NJ
PTC THERAPEUTICS, INC.

PTC Therapeutics develops and commercializes medicines for rare genetic and oncology diseases using modalities including small-molecule drugs and other approaches. The company has approved products on the market (Translarna for a form of muscular dystrophy, Sephience for phenylketonuria) and is advancing pipeline candidates in clinical development, including votoplam for Huntington's disease and vatiquinone for Friedreich's ataxia, with some programs potentially eligible for accelerated regulatory pathways.

Price history not yet available for PTCT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar